Cargando…

Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases

Phage therapy has been overshadowed by antibiotics for decades. However, it is being revisited as a powerful approach against antimicrobial-resistant bacteria. As bacterial microbiota have been mechanistically linked to gastrointestinal and liver diseases, precise editing of the gut microbiota via t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiki, Jumpei, Schnabl, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641246/
https://www.ncbi.nlm.nih.gov/pubmed/37965159
http://dx.doi.org/10.1016/j.jhepr.2023.100909
_version_ 1785146734202060800
author Fujiki, Jumpei
Schnabl, Bernd
author_facet Fujiki, Jumpei
Schnabl, Bernd
author_sort Fujiki, Jumpei
collection PubMed
description Phage therapy has been overshadowed by antibiotics for decades. However, it is being revisited as a powerful approach against antimicrobial-resistant bacteria. As bacterial microbiota have been mechanistically linked to gastrointestinal and liver diseases, precise editing of the gut microbiota via the selective bactericidal action of phages has prompted renewed interest in phage therapy. In this review, we summarise the basic virological properties of phages and the latest findings on the composition of the intestinal phageome and the changes associated with liver diseases. We also review preclinical and clinical studies assessing phage therapy for the treatment of gastrointestinal and liver diseases, as well as future prospects and challenges.
format Online
Article
Text
id pubmed-10641246
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106412462023-11-14 Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases Fujiki, Jumpei Schnabl, Bernd JHEP Rep Review Phage therapy has been overshadowed by antibiotics for decades. However, it is being revisited as a powerful approach against antimicrobial-resistant bacteria. As bacterial microbiota have been mechanistically linked to gastrointestinal and liver diseases, precise editing of the gut microbiota via the selective bactericidal action of phages has prompted renewed interest in phage therapy. In this review, we summarise the basic virological properties of phages and the latest findings on the composition of the intestinal phageome and the changes associated with liver diseases. We also review preclinical and clinical studies assessing phage therapy for the treatment of gastrointestinal and liver diseases, as well as future prospects and challenges. Elsevier 2023-09-23 /pmc/articles/PMC10641246/ /pubmed/37965159 http://dx.doi.org/10.1016/j.jhepr.2023.100909 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Fujiki, Jumpei
Schnabl, Bernd
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
title Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
title_full Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
title_fullStr Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
title_full_unstemmed Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
title_short Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
title_sort phage therapy: targeting intestinal bacterial microbiota for the treatment of liver diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641246/
https://www.ncbi.nlm.nih.gov/pubmed/37965159
http://dx.doi.org/10.1016/j.jhepr.2023.100909
work_keys_str_mv AT fujikijumpei phagetherapytargetingintestinalbacterialmicrobiotaforthetreatmentofliverdiseases
AT schnablbernd phagetherapytargetingintestinalbacterialmicrobiotaforthetreatmentofliverdiseases